Global Injectable Benzodiazepines Industry Poised for Remarkable Growth: Sales Expected to Reach US$ 356 Million by 2032

The Global Injectable Benzodiazepines Industry is on the brink of a substantial transformation, with a projected Compound Annual Growth Rate (CAGR) of 2.7% from 2022 to 2032. According to market insights, sales of injectable benzodiazepines are expected to reach a remarkable US$ 356 million, reflecting the increasing demand for these critical pharmaceuticals in addressing escalating mental health concerns.

The world has witnessed an unprecedented shift in mental health dynamics, prompting a surge in the demand for injectable benzodiazepines. The COVID-19 pandemic has had a profound impact on individuals’ mental well-being, transcending demographic boundaries and affecting those irrespective of their prior mental health status. This surge in mental health challenges has driven the sales of the Global Injectable Benzodiazepines Industry to new heights, as individuals and healthcare providers seek effective solutions to address anxiety, stress, and related conditions.

Key Takeaways of Injectable Benzodiazepine Market Study

• Lorazepam injectable benzodiazepine accounted for the highest share in the injectable benzodiazepine market in 2019
• Seizures and anxiety among leading ailments where injectable benzodiazepines are administered
• North America and Europe are expected to hold a noteworthy revenue share of about 60% in the global injectable benzodiazepine market in 2020

Low cost manufacturing and large patient pools in Asian countries expected to be a key growth driver in the forecast period

“Growing incidences of seizures and anxiety followed by demand for generics to boost the global injectable benzodiazepine market,” says an FMI Analyst.

Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-11724

Research Collaborations: Key to Sustenance
The market players are emphasizing on expanding their manufacturing facilities with introduction of cost-effective and generic drugs and also venturing into strategic partnerships.

• In Jan 2020, Hospital Sales Force from Xellia signed an agreement with Eton to promote Biorphen in the institutions that prefer having ready-to-use injectable formulations
• In Oct 2019, KemPharm’s APADAZ (to treat ADHD) got licensed to KVK-Tech, Inc. to make its generic AG-APADAZ available all across the US
• In Dec 2018, Hikma Pharmaceuticals came up with clobazam oral suspension as well as tablets, the generic equivalent to “Onfi” (marketed by H. Lundbeck A/S)

What else is in the report?
Future market insights offer a unique perspective and actionable insights on injectable benzodiazepine market in its latest study, presenting historical demand assessment from 2015 – 2019 and projections from 2020–2030 based on drug class (diazepam, lorazepam, and midazolam), by time of action (short acting long acting), by indication (agitation & aggression, anxiety, alcohol withdrawal, muscle spasm, seizures, tetanus, sedation, anesthesia insomnia, and status epilepticus), by distribution channel (hospital pharmacies, retail pharmacies and online pharmacies) in seven key regions.

Examining the core assumptions of the study. Ask from Market Research Expert
https://www.futuremarketinsights.com/ask-question/rep-gb-11724

Key Segments of Global Injectable Benzodiazepines Industry
FMI’s study on the injectable benzodiazepines market offers information divided into three important segments— drug class, indication, time of action, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Drug Class

• Diazepam
• Lorazepam
• Midazolam

Time of Action

• Short Acting
• Long Acting

Indication

• Agitation & Aggression
• Anxiety
• Alcohol Withdrawal
• Muscle Spasm
• Seizures
• Tetanus
• Sedation
• Anaesthesia
• Insomnia
• Status Epilepticus

Distribution Channel

• Hospital
• Ambulatory Surgical centers
• Diagnostics Centers

Region

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa

Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/11724

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube